HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO HighTide Therapeutics (PHIP Updates) - Some Shareholders Have Chosen to Quit in Advance

China Healthcare Weekly (Dec.15)-BMS/Biokin $8.4B Eye-Popping Deal, NRDL Negotiation Result, Haoyuan

China's Central Economic Work Conference – Something You May Not Be Aware Of

Pre-IPO Wuhan YZY Biopharma - Both R&D and Commercialization Capabilities Have yet to Be Proven

Pre-IPO Kelun Biotech (PHIP Updates) - Some Points Worth the Attention

2023H2 China Healthcare Investment Strategy and Top Pick

China Traditional Chinese Medicine (570.HK) - The Privatization Rumor and the Outlook

Equity Capital Markets

HighTide Therapeutics / Equity Capital Markets

<ul>
<li>The mechanism of NASH has not yet been accurately determined. Among the major players, FDA has postponed the approval of OCA (FXR) for NASH. THR-β is currently the most promising. </li>
<li>HighTide claims that HTD1801 is able to achieve the goal of improving effectiveness and reducing toxicity. However, HTD1801 hasn’t reached pathological endpoints. We’ll have to wait for future clinical data.</li>
<li>This Company actually has high risk due to cash shortage and uncertain R&amp;D progress, which could lead to lower-than-expected stock price performance. We are conservative about HighTide based on analysis.</li>
</ul>


The mechanism of NASH has not yet been accurately determined. Among the major players, FDA has postponed the approval of OCA (FXR) for NASH. THR-β is currently the most promising. 
HighTide claims that HTD1801 is able to achieve the goal of improving effectiveness and reducing toxicity. However, HTD1801 hasn’t reached pathological endpoints. We’ll have to wait for future clinical data.
This Company actually has high risk due to cash shortage and uncertain R&amp;D progress, which could lead to lower-than-expected stock price performance. We are conservative about HighTide based on analysis.


Pre-IPO HighTide Therapeutics - Its Outlook in NASH Field Is Not Optimistic, with High Risks